---
document_datetime: 2025-10-14 12:11:19
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/evusheld-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: evusheld-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.1990647
conversion_datetime: 2025-12-27 14:54:55.869614
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                                                               | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| IB/0019              | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol | 11/10/2024                                  |                                             | SmPC and PL                      |                                   |
| PSUSA/10992          | Periodic Safety Update EU Single assessment -                                                                                                                                       | 13/06/2024                                  | n/a                                         |                                  | PRAC Recommendation - maintenance |

EVUSHELD Procedural steps taken and scientific information after the authorisation Application number Scope Commission Decision Issued 2 / amended Product Information affected 3 Summary IB/0019 B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol SmPC and PL PSUSA/10992 Periodic Safety Update EU Single assessment n/a PRAC Recommendation - maintenance Medicinal product no longer authorised

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| /202311             | tixagevimab / cilgavimab (Evusheld)                                                                                                                                                                                                                                                                                                                                                                             |            |               |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0018             | Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to update the warning on antiviral resistance, based on the latest neutralisation data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 30/05/2024 | 04/10/2024 no | SmPC, Labelling and PL | Circulating SARS-CoV-2 viral variants may be associated with resistance to monoclonal antibodies such as tixagevimab and cilgavimab. The in vitro neutralisation activity of EVUSHELD against SARS-CoV-2 viral variants are shown in the Summary of the Product Characteristics. Patients who received EVUSHELD prophylactically should be informed of the potential for breakthrough infections to occur. The duration of protection for variants with an observed decrease in in-vitro neutralisation activity is uncertain. Patients should be instructed to promptly seek medical advice if signs or symptoms of COVID-19 occur (the most common symptoms include fever, cough, tiredness and loss of taste or smell; the most serious symptoms include difficulty breathing or shortness of breath, loss of speech or mobility, or confusion and chest pain). Decisions regarding the use of EVUSHELD for the treatment of COVID-19 should take into consideration what is known about the characteristics of the circulating SARS-CoV-2 viral variants, including geographical prevalence. longer authorised |
| PSUSA/10992 /202305 | Periodic Safety Update EU Single assessment - tixagevimab / cilgavimab (Evusheld) product                                                                                                                                                                                                                                                                                                                       | 30/11/2023 | n/a           |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0013             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required Medicinal                                                                                                        | 26/10/2023 | n/a           |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| II/0009/G           | This was an application for a group of variations. Grouped application comprising two type II variations (REC 23) as follows: C.I.4 - Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and satefy information based on final results from study TACKLE (D8851C00001). C.I.4 - Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy and safety information based on final results from studies PROVENT (D8850C00002) and STORM CHASER (D8850C00003). In addition, the MAH took the opportunity to add some editorial changes. The RMP version 4.2 is also updated. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance product   | 12/10/2023   | 04/10/2024 no   | SmPC            | SmPC new text The PK modelling ,efficacy and safety information included in the SmPC for Evusheld is updated considering the final data analysis coming from PROVENT, STORM CHASER and TACKLE studies. For more information, please refer to the Summary of Product Characteristics. longer authorised   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0015           | data A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 02/10/2023   | 04/10/2024      | Annex II and PL |                                                                                                                                                                                                                                                                                                          |
| PSUSA/10992 /202211 | Periodic Safety Update EU Single assessment - tixagevimab / cilgavimab (Evusheld)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/06/2023   | 16/08/2023      | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10992/202211.                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0012   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                              | 31/07/2023   | n/a           |                                                                                      |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|--------------------------------------------------------------------------------------|
| IA/0011   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                    | 05/06/2023   | n/a           | authorised                                                                           |
| II/0007/G | This was an application for a group of variations. B.II.f.1.b.4 - Stability of FP - Extension of the shelf life of the finished product - Based on extrapolation of stability data not in accordance with ICH/VICH guidelines B.II.f.1.b.4 - Stability of FP - Extension of the shelf life of the finished product - Based on extrapolation of stability data not in accordance with ICH/VICH guidelines product                                    | 30/03/2023   | 16/08/2023 no | SmPC The SmPC section 6.3. has been updated as follows: Unopened vial 2 years longer |
| II/0006/G | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method Medicinal | 16/02/2023   | n/a           |                                                                                      |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/10992 /202205   | Periodic Safety Update EU Single assessment - tixagevimab / cilgavimab (Evusheld)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 01/12/2022   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005/G             | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 21/11/2022   | n/a no     | longer      | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0001               | specification limits C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one Medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                     | 15/09/2022   | 16/09/2022 | SmPC and PL | Extension of indication to include treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19. As a consequence, sections 4.1, 4.2, 4.4,4.8, 4.9, 5.1, 5.2 ,6.3, 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to make some editorial changes. Version 2.0 of the RMP has also been submitted. Please refer to Scientific Discussion - 'Evusheld/H/C/005788/II/0001' |

<div style=\"page-break-after: always\"></div>

<!-- image -->